Matinas BioPharma Holdings (NASDAQ: MTNB) and Alkermes PLC (NASDAQ:ALKS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Matinas BioPharma Holdings and Alkermes PLC, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Matinas BioPharma Holdings 0 0 3 0 3.00
Alkermes PLC 0 4 4 0 2.50

Matinas BioPharma Holdings currently has a consensus price target of $7.67, suggesting a potential upside of 472.14%. Alkermes PLC has a consensus price target of $63.63, suggesting a potential upside of 29.42%. Given Matinas BioPharma Holdings’ stronger consensus rating and higher probable upside, equities analysts plainly believe Matinas BioPharma Holdings is more favorable than Alkermes PLC.

Valuation & Earnings

This table compares Matinas BioPharma Holdings and Alkermes PLC’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Matinas BioPharma Holdings $59,875.00 2,058.33 -$12.81 million N/A N/A
Alkermes PLC $804.37 million 9.39 -$103.30 million ($1.28) -38.41

Matinas BioPharma Holdings has higher revenue, but lower earnings than Alkermes PLC.

Institutional and Insider Ownership

99.1% of Alkermes PLC shares are owned by institutional investors. 5.3% of Alkermes PLC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Matinas BioPharma Holdings and Alkermes PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Matinas BioPharma Holdings -30,034.20% -1,227.85% -113.25%
Alkermes PLC -24.33% -9.12% -6.40%

Summary

Alkermes PLC beats Matinas BioPharma Holdings on 7 of the 11 factors compared between the two stocks.

Matinas BioPharma Holdings Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.